Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma

19 Mar 2015

Abstract excerpt

BACKGROUND: Glioblastoma (GBM) is the most common and aggressive form of brain cancer. Our previous studies demonstrated that combined inhibition of HDAC and KDM1A increases apoptotic cell death in vitro. However, whether this combination also increases death of the glioma stem cell (GSC) population or has an effect in vivo is yet to be determined. Therefore, we evaluated the translational potential of combined...

Topics

Join the communities discussing this publication.

Epigenetics and DNA Methylation
Glioma Diagnosis and Treatment
Histone Deacetylase Inhibitors Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25795306
DOI: 10.1093/neuonc/nov041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical activity of combined HDAC and KDM1A inhibition in glioblastomaPMID 25795306Read ↗

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read ↗

Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastomaSemantic proximity Read ↗

Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for GlioblastomaSemantic proximity Read ↗

Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells.Semantic proximity Read ↗

MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell LinesSemantic proximity Read ↗

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulationSemantic proximity Read ↗

PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomideSemantic proximity Read ↗

Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical ModelsSemantic proximity Read ↗

DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cellsSemantic proximity Read ↗

Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathwaySemantic proximity Read ↗

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatmentSemantic proximity Read ↗

A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.